RxDoctor Payments Data

Abbe Rosenbaum, MD

Cardiovascular Disease · South Miami, FLNPI 1356304554

Payments from drug & device makers

$1,747in general payments, 2019–2025

Across 89 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$316
  • E.r. Squibb & Sons, L.L.C.$167
  • Amgen$123
  • Heartflow, Inc.$118
  • Sanofi-aventis U.S. LLC$86
  • Novartis$84
  • plus $851 from 20 others

What the payments were for

  • Food & beverage$1,71598%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,747 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$668,474
Medicare patients
846
Services billed
7,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$219,761
EntrestoSacubitril/Valsartan60$57,033
XareltoRivaroxaban39$54,923
Repatha SureclickEvolocumab56$48,379
MounjaroTirzepatide34$39,188
WegovySemaglutide22$31,047
OzempicSemaglutide26$28,786
JardianceEmpagliflozin18$27,106
Nebivolol Hcl106$9,171
Metoprolol Succinate453$8,230
Atorvastatin Calcium673$7,635
Losartan Potassium491$6,838
Rosuvastatin Calcium383$6,073
Amlodipine Besylate523$4,955
Clonidine33$4,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$316$219,761170 claims
Novo NordiskWegovy, Ozempic$66$59,83448 claims
NovartisEntresto$84$57,03360 claims
Johnson & JohnsonXarelto$12$54,92339 claims
Lilly USA, LLCMounjaro$31$39,18834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →